CIC
PCRX icon

Chase Investment Counsel’s Pacira BioSciences PCRX Stock Holding History

Chase Investment Counsel’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-44,023
Closed -$3.36M – 122
2022
Q1 		$3.36M Buy
+44,023
New +$2.93M 1.47% 24

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Chase Investment Counsel's PCRX Position: Q2 2022 in Review

Chase Investment Counsel sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 44,023 shares — an estimated $3.36M sold.

Chase Investment Counsel first reported a position in PCRX in Q1 2022 and held it in 1 quarter. The position peaked at $3.36M in Q1 2022. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

  • Chase Investment Counsel reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
  • Chase Investment Counsel sold 44,023 Pacira BioSciences shares in Q2 2022, an estimated $3.36M.
  • Chase Investment Counsel first reported a position in Pacira BioSciences in Q1 2022 and held it in 1 quarter.
  • Chase Investment Counsel's Pacira BioSciences position peaked at $3.36M in Q1 2022.
  • 284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Chase Investment Counsel's 13F filing for Q2 2022, filed 26 Jul 2022.